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peanut 5 (21%), egg 3 (13%), fish 1 (4%) and fruits 1 (4%). Peanut could be reintroduced 
to all children after CRD, egg and milk after specific IgE IVD. Prior to the introduction 
of food a secondary care specialist food provocation was performed to confirm the 
IVD result. ConClusions: CRD ISAC was beneficial in 54% of the cases and in 21% 
of the cases it was critical for decision making. The aim of the study was reached as 
avoidance diets decreased by 63%. The results indicate, even with low patient recruit-
ment, it is likely that introducing ISAC IVD to traditional diagnostic algorithm can be 
considered cost-effective, with an average cost per avoided unnecessary diet for 480 
EURs per child. To confirm the findings a larger study will be executed.
PRS42
CoSt EffECtivEnESS AnAlySiS of RESPiRAtoRy SynCytiAl viRuS 
infECtion PRoPhylAxiS in ChildREn With CongEnitAl hEARt diSEASE
Cintra M.A.C.T, Santos M.S., Correia M.G., Tura B.R.
National Institute of Cardiology, Rio de Janeiro, Brazil
objeCtives: Respiratory syncytial virus (RSV) is the leading cause of acute lower 
respiratory illness in children under two years of age. In Brazil, the VSR is the cause 
of 54.1% of all hospitalizations for pneumonia /bronchiolitis in infants under one 
year old, reaching up to 70% during the epidemic periods. Congenital heart disease 
(CHD) is an important risk factor for morbidity and mortality of RSV infection. This 
study performed a cost effectiveness analysis of Palivizumab (PVZ) to prevent RSV 
infection in infants undergoing cardiac surgery for correction of CHD. Methods: 
Three Systematic Reviews (SR) of literature were performed, in Medline, Cochrane 
and LILACS, for efficacy, safety of PVZ and the prevalence of RSV in infants in Brazil. 
The economic evaluation developed a decision analytic model to estimate the cost-
effectiveness ratio of using PVZ for prophylaxis of RSV infection in children under-
going cardiac surgery, from the perspective of Public Health System, with the time 
horizon of the postoperatively period. Results: Efficacy search (478 titles) showed 
that PVZ reduces hospitalization for children with CHD by 45%. Safety search (67 
titles) showed that the PVZ is safe for this population and the prevalence of RSV in 
Brazil search (120 titles) showed that in children hospitalized with lower respiratory 
tract infection there is a prevalence of 24.35% of RSV infection. The analytical model 
showed an incremental cost-effectiveness ratio of USD863.3 per day of hospitalization 
avoided and incremental cost-effectiveness ratio of USD132,398.9 per complication 
avoided. ConClusions: The prevalence of RSV in Brazil is 24.35%. PVZ was effective 
and safe to prevent severe RSV infection in children under two years of age with CHD, 
but at a high cost to avoid an outcome. Its use has shown a significant decrease in 
hospitalization of children receiving medication. Studies published worldwide are 
controversial, requiring discussion for the implementation of the therapy in Brazil.
PRS43
CoSt EffECtivEnESS AnAlySiS of vAREniClinE uSE foR Smoking 
CESSAtion in thE City of São PAulo fRom thE PubliC hEAlth SyStEm 
PERSPECtivE
Portela L.D.1, Issa J.S.1, Santos V.G.1, Santos P.C.J.D.L.1, Pereira A.D.C.1, Cipriano S.L.1, Ferreira C.N.2, 
Manfrin D.F.2
1Heart Institute (InCor), University of Sao Paulo Medical School, São Paulo, Brazil, 2Pfizer, Inc., São 
Paulo, Brazil
objeCtives: Drugs for smoking cessation are considered of great importance to the 
decline of this epidemic, as smoking is the largest preventable cause of death world-
wide. This study aimed to evaluate the cost effectiveness of varenicline compared 
with bupropion and NRT (gum and patches) in the treatment of smoking population 
from São Paulo, Brazil’s city. Methods: Effectiveness data of 6-months of treatment 
were evaluated from a sample of patients (504) in the outpatient smoking care of 
Instituto do Coraçãoem São Paulo-Brasil (InCor). Direct drug costs were extracted from 
the Health System Prices Database. A Decision Tree Model was used for the analysis of 
Cost Effectiveness (CE) and Incremental Cost-Effectiveness Ratio (ICER), considering 
varenicline monotherapy as standard. Results: The CEs obtained were BRL 1.31, BRL 
1.34, BRL 1.88, BRL 3.09 and BRL 1.98 billion in the use of varenicline monotherapy, 
varenicline associated with bupropion, bupropion associated with gum, bupropion 
associated with NRT (gum and patches) and NRT in gum and patches,respectively. 
The ICERs were BRL 1.66 billion, BRL 153 million and per patient of BRL 1,400 and BRL 
138,41 for varenicline associated with bupropion and bupropion associated with gum 
respectively and ICERs for bupropion associated with NRT and isolated NRT respec-
tively were BRL 1.65 billion and BRL 164 billion (dominant). ConClusions: According 
to the results, treatment with varenicline (monotherapy) is cost effective for all com-
parators and cost saving when compared to NRT and bupropion associated with NRT.
PRS44
CoSt-EffECtivEnESS AnAlySiS of A nEW EPinEPhRinE Auto-injECtoR foR 
thE tREAtmEnt of food-AllERgy REACtionS: dECiSion modElling uSing 
SoCiEtAl PERSPECtivE
Patel A.M, Saxena K., Holdford D.A.
Virginia Commonwealth University, Richmond, VA, USA
objeCtives: Food allergy affects around 15 million Americans with an annual eco-
nomic burden of over $25 billion. Guidelines emphasize prompt use of epinephrine 
auto-injector (EAI) for emergency treatment of allergic reactions. This study was 
executed to assess the cost-effectiveness of a new EAI device among patients expe-
riencing life-threatening food-allergy reactions. Methods: An episodic Decision-
analysis model was developed to estimate the incremental cost-effectiveness ratio 
(ICER) associated with the new EAI compared to standard EAI, from a societal per-
spective. Both EAIs contain the same active drug of equal strength, but have different 
delivery systems. The model assumed a cohort of “at-risk” patients in the US popula-
tion, with moderate-to-severe food-allergy reaction. Treatment success was defined 
as epinephrine self-injection without any errors. Data were obtained from published 
sources including patient survey studies. Direct costs (drug cost, hospitalization and 
emergency department cost) and indirect costs (lost work-productivity cost) asso-
ciated with the treatments were calculated in 2013 US$. Sensitivity analyses were 
performed on drug costs and treatment success rates. TreeAge Pro 2011 software 
represent a cost-effective alternative to salmeterol and ipratropium if daily cost for 
tiotropium can be reduced to a reasonable level in Taiwan’s National Health Insurance.
PRS39
Amino ACid foRmulA AS A fiRSt-linE diAgnoSiS tool in infAntS With 
CoW’S milk AllERgy (CmA): A CoSt-EffECtivEnESS AnAlySiS undER thE 
bRAziliAn PubliC hEAlth CARE SyStEm PERSPECtivE
Castro A.P.B.M.1, Morais M.B.D.1, Cardoso A.L.1, Vieira M.C.2, Spolidoro J.V.N.3, Nishikawa A.M.4, 
Clark O.A.C.4
1Universidade de São Paulo, Brazil, 2Hospital Pequeno Príncipe, Brazil, 3Pontifícia Universidade 
Católica do Rio Grande do Sul, Brazil, 4Evidências, Campinas, Brazil
objeCtives: Cow’s milk allergy (CMA) is the main cause of food allergy in infants, 
resulting in life-threatening events such as anaphylaxis, impairment in growth 
and quality of life. CMA symptoms are also related to other diseases, making the 
differential diagnosis crucial for an earlier effective treatment, avoiding waste of 
resources. Amino acid formula (AAF) is an alternative in treatment of CMA patients, 
but it can also be used as a diagnostic tool for children with CMA suspicion, shorten-
ing the time for diagnosis, which may reduce resources use. Our goal is to estimate 
the cost-effectiveness of an alternative practice (AP) using AAF as a diagnostic tool 
for CMA followed by treatment according to current practice, compared to those 
currently (CP) used in Brazil, under the perspective of the public health care sys-
tem. Methods: A decision model was constructed depicting the CMA manage-
ment, with a time horizon until patients turned three years old, when most of CMAs 
are resolved. Model inputs were based on literature review and opinions of allergists/
gastroenterologists/pediatricians. Exchange rate was 1.00USD = 2.30BRL. Only direct 
costs were considered, such as formula, tests, allergy treatment, medical visits and 
hospital admissions. Results were shown as incremental costs/relapses avoided. 
Deterministic and probabilistic sensitivity analyses were performed. Results: 
The CP presented rates of 25.4% and 9.3% of diseases other than CMA after 8 and 
12 weeks respectively versus 34% in 2 weeks for AP. With this difference an effec-
tive treatment could be established in a shorter time, diminishing the waste of 
resources. The final analysis showed that the AP using AAF for diagnosis is domi-
nant (USD1,345 and 900.6 non-symptomatic days) compared to CP (USD1,476 and 
876.0 non-symptomatic days). ConClusions: AP enabled an earlier CMA diagno-
sis, avoiding waste of resources, allowing the establishment of prompt effective 
treatments and leading to higher compliance with clinicians’ recommendations.
PRS40
CoSt-EffECtivEnESS AnAlySiS of nuRSE-AdminiStEREd oRAl 
CoRtiCoStERoidS At tRiAgE in PEdiAtRiC ASthmA
Loncar M.1, Coyle D.1, Barrowman N.2, Zemek R.3
1University of Ottawa, Ottawa, ON, Canada, 2Children’s Hospital of Eastern Ontario Research 
Institute, Ottawa, ON, Canada, 3Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada
objeCtives: Despite evidence supporting the need for oral corticosteroid use in 
the management of acute pediatric asthma exacerbations, delays in administration 
are still common. This often leads to an increase in inpatient admissions and more 
time spent in the emergency department (ED). Using data from a time-series con-
trolled trial, the objective of this study was to assess the cost-effectiveness of triage 
nurse-administered oral corticosteroids (NAC) in children presenting to the ED with 
moderate to severe asthma exacerbations prior to physician assessment. Methods: 
Resource use and cost data for 644 acutely asthmatic patients enrolled in the con-
trolled trial comparing NAC with standard care was used. Analysis assessed the per 
patient health care system costs for both the NAC (after) phase and the physician-
ordered (before) phase over the trial’s 8-month follow-up. Uncertainty around esti-
mates was assessed through nonparametric bootstrapping which allowed calculation 
of the probability that NAC was cost-effective for different threshold values. Net 
benefit regression was used to estimate the incremental net benefit (INB) adjusted 
for potential confounders for reduced time in ED. Results: NAC was dominant 
over standard care as it was both less costly (Canadian $499.24 versus $724.90) and 
mean time to clinical improvement was shorter (218 minutes versus 264 minutes). 
The probability that NAC was cost-effective was greater than 0.98 for all threshold 
values of reduction in time with symptoms. Sensitivity analyses adopting various 
alternative assumptions found only modest differences in cost savings between the 
phases, but did not change the conclusions of the analysis. Results of the net benefit 
regression provided further evidence that NAC was cost-effective. ConClusions: 
Triage nurse initiation of oral corticosteroids before physician assessment is a cost-
effective strategy for treating children with moderate to severe asthma exacerbations 
in pediatric ED.
PRS41
hEAlth EConomiC bEnEfit of inCluding ComPonEnt RESolvEd 
diAgnoStiCS (CRd) (immunoCAP iSAC) in in vitRo diAgnoStiC (ivd) 
AlgoRithm in PRoSPECtivE tRiAl With SuSPECtEd food AllERgiC 
SChool ChildREn in finlAnd
Hermansson L.L.1, Pensamo E.2, Korhonen K.3, Rantanen S.3, Isoaho R.2, Savolainen J.2
1Thermo Fisher Scientific, Uppsala, Sweden, 2University of Turku, Turku, Finland, 3Härkätie 
Primary Care Center, Lieto, Finland
objeCtives: Aim of study, in accordance to Finnish Allergy Program 2008-2018, is 
to decrease food avoidance diets by 50 %. Here focus is in algorithm with IVD and 
patient history in primary care school children. Health economic benefit of CRD, ISAC, 
is evaluated. Methods: Database analysis at Härkätie Primary Care Unit, including 
2317 school children in Finland indicated that 199 children (8.6%) are on avoidance 
diet ex. celiac disease. There is 37 (1.6 %) milk and 32 (1,4%) egg free diets. Peanut and 
hazelnut allergy is indexed for 39 children and 6 are indicated as soya allergic. History 
of anaphylaxis was noted in 7. Avoidance recommendation is provided by parents 
and has direct impact in costs and patient’s quality of life. The 199 children were 
contacted by letter, and 36 (18 %) were interviewed by physician. Of those, 24 children 
agreed to take part in the study with IVD (67%). Results: An unnecessary diet was 
concluded for 15, which is 63% of children included in the study: cow’s milk 7 (29%), 
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medication utilization. Multivariate logistic and linear regression analyses were 
employed. Results: The study sample (n= 32,172) was 15.0±14.5 years old and con-
troller therapy adherence was 32.2%±19.7%. The mean number of SABA claims was 
3.7±3.1; most had 1-5 claims (73.2%), whereas 19.4% had ≥ 6 claims and 7.4% had 
none. The mean number of OCS claims was 1.0±1.4. Patients with ≥ 6 SABA claims 
had 0.7 more OCS claims compared to patients with < 6 claims for SABA (p< 0.0001). 
LTC-adherent (PDC≥ 50%) patients were 96.7% (OR= 1.967;95%CI= 1.826-2.120) more 
likely to have ≥ 6 SABA claims when compared to nonadherent (PDC< 50%) patients 
(p< 0.0001). LTC-adherent patients had 0.11 fewer OCS claims compared to non-
adherent patients (p< 0.0001). The odds of having ≥ 6 SABA claims were higher for 
concurrent dual therapy users, older age, males, African-Americans, and higher 
number of non-study medications (p< 0.0001). Dual therapy users, younger age, 
Hispanic ethnicity, and higher number of non-study medications were associated 
with an increase in OCS use (p< 0.005). ConClusions: Although there was a posi-
tive relationship between LTC adherence and SABA use, increased SABA use served 
as a predictor of increased OCS use, which indicates poor asthma control. Health 
care providers should be aware of SABA use among patients who are both adherent 
and nonadherent to asthma controller medications.
PRS48
imPACt of mEdiCAtion AdhEREnCE And PRESEnCE of ComoRbid 
dEPRESSivE diSoRdER on hEAlth CARE CoStS Among tExAS mEdiCAid 
PAtiEntS With ASthmA
Gupte K.P., Kim G., Barner J.C.
The University of Texas at Austin, Austin, TX, USA
objeCtives: To determine if there is a significant difference in asthma-related 
health care costs (HCC) and adherence to asthma controllers between patients 
with asthma and comorbid depressive disorder (A+D) vs. patients with asthma 
alone (A). Methods: Texas Medicaid medical and prescription claims from 
1/1/07-10/31/11 were extracted for adults (18-63 years) who had ≥ 2 asthma con-
trollers in the A group, and additionally ≥ 2 antidepressants in the A+D group. 
The index date was the first date of asthma controller use with no previous use 
in the 6-month pre-index period. Patients were followed for 12 months. HCC (2011 
dollars) included asthma-related prescriptions, inpatient, and outpatient costs. 
Proportion of days covered (PDC) was used to assess adherence, and covariates 
included asthma-related pre-index HCC, inpatient visit (Yes/No), numbers of 
outpatient visits and prescriptions, asthma controller class, severity and demo-
graphic characteristics. Descriptive statistics, Wilcoxon test and generalized linear 
model (gamma distribution and log link) were used. Results: Median prescrip-
tion costs (n= 3626) were significantly (p< 0.05) higher, while inpatient+outpatient 
median costs were lower for the A+D vs. A groups ($873.47 vs. $787.28; $47.68 
vs. $73.89, respectively). The median (Mean±SD) asthma-related HCC for A group 
(n= 3400) was not significantly different from the A+D group (n= 226): [($1038.67, 
$1349.85±$1140.16) vs. ($1103.70, $1416.49±$1154.57), p= 0.2198, respectively]. After 
controlling for covariates, regression results showed that compared to A group, 
the A+D group had significantly lower asthma-related HCC (p< 0.0001). Asthma 
controller adherence was significantly and positively related to HCC (p< 0.0001). In 
the A+D group, patients who were more adherent to antidepressants were more 
adherent to asthma controllers. ConClusions: Patients with A+D had significantly 
lower asthma-related HCC than those with A. In A+D, the higher costs of asthma-related 
prescriptions were offset by the lower costs of inpatient+outpatient claims. Patients 
with comorbid asthma and depression should adhere to both asthma controller and 
antidepressant medications.
PRS49
tREAtmEnt PERSiStEnCE ComPARiSon bEtWEEn nEbulizEd 
foRmulAtionS of ARfoRmotERol And foRmotERol in thE tREAtmEnt 
of ChRoniC obStRuCtivE PulmonARy diSEASE
Bollu V.1, Chen Y.J.2, Makin C.2
1Sunovion Pharmaceuticals Inc., Marlborough, MA, USA, 2IMS Health, Alexandria, VA, USA
objeCtives: Treatment persistence can be a good indicator of drug efficacy and 
tolerability. Inhaled long-acting bronchodilators (e.g., long-acting β 2-agonists 
[LABAs]) are the recommended maintenance treatment in moderate-to-severe 
chronic obstructive pulmonary disease (COPD). Arformoterol and formoterol are 
the only two available nebulized LABAs. There is limited real-world head-to-head 
comparative evidence for nebulized LABAs. The objective is to evaluate the differ-
ence in their treatment persistence. Methods: This retrospective cohort study 
of the PharMetrics Plus claims database included eligible (continuous health plan 
enrollment 180-day pre- and 360-day post-index) patients > 35 years; with ≥ 2 pre-
scriptions of nebulized LABAs between 2008-2011 (first use as index); COPD diagno-
sis (ICD-9-CM 491.x, 492.x, 496.x) with ≥ 2 outpatient or ≥ 1 inpatient claims. Patients 
were excluded if they received nebulized LABA treatment or asthma diagnosis in 
the pre-index period. Persistence was defined as days from index to discontinua-
tion (gap of ≥ 60 days) or end of study. Chi-square and t-test were used to compare 
two cohorts (alpha= 0.05). Cox proportional hazards models were used to evaluate 
discontinuation risk 180- and 360-days post-index as a function of nebulized LABAs, 
age, physician specialty, comorbidities, initiation timing, and pre-index health care 
spending. Results: A total of 1,041 eligible patients (arformoterol= 672, formo-
terol= 369) were included (mean age= 69.4 years, 47.5% females). Compared to formo-
terol patients, arformoterol patients had longer treatment persistence (mean±SD: 
210±133 vs. 192±137 days, p= 0.0356), and lower predicted discontinuation risk 
(hazard ratio [HR]= 0.78 [95% CI 0.65-0.93] in 180-day post-index and HR= 0.87 [95% 
CI 0.75-1.00] in 360-day post-index models). Nebulized LABAs, non-pulmonologist 
prescribing, pre-index depression, and lower pre-index health care spending were 
associated with higher discontinuation risk in both 180- and 360-day Cox models. 
Younger age (35-54 vs. 65+ years) and pre-index diabetes additionally predicted 
higher discontinuation risk in 360-day Cox model. ConClusions: COPD patients 
on arformoterol had a higher treatment persistence compared to formoterol 
patients in this retrospective claims analysis.
was used for the analyses. Results: In the base-case analysis, the standard EAI 
showed an incremental cost of $63 and an incremental effectiveness of negative 
33%, per allergic episode. Overall, the ICER showed a cost saving of approximately 
$190 for the new EAI over the standard EAI, per allergic episode. The sensitivity 
analyses indicated a continuous dominance of the new EAI over plausible range 
of drug costs and injection success rate. These results were reversed when the 
success rate with standard EAI was assumed to be over 50% (base-case value of 
12.5%). ConClusions: Based on the available data and our model assumptions, 
treatment of emergency food-allergy reaction with the new EAI was found to be 
more cost-effective compared to standard EAI. This can be attributed to an improve-
ment in the delivery system resulting in correct injection use.
PRS45
A mARkov CoSt-EffECtivEnESS modEl ComPARing flutiCASonE 
PRoPionAtE/SAlmEtERol CombinAtion (SfC) And momEtASonE fuRoAtE/
foRmotERol fumARAtE dEhydRAtE (mf) in thE mAnAgEmEnt of ASthmA
Verma D., Yang Y., Bowlin E.M.
University of Mississippi, University, MS, USA
objeCtives: Successful asthma management reduces the morbidity and mortality 
associated with the disease as well as the costs associated with treating complica-
tions. Several treatment options exist for asthma management, many that include a 
steroid in combination with a long-acting beta agonist (LABA), which are referred to 
as “controller medications.” The purpose of this project was to estimate the costs and 
effectiveness and to determine the cost-effectiveness of two combination controller 
medications: fluticasone propionate/salmeterol combination (SFC) and mometasone 
furoate/formoterol fumarate dehydrate (MF). Methods: A Markov disease state-
transition model was constructed to estimate the costs and effectiveness of SFC and 
MF. The analysis was conducted from a U.S. health care system’s perspective. Cost 
data for SFC were obtained from a published study evaluating the costs of managing 
asthma exacerbations in the UK in primary and secondary care and cost data for 
MF were derived by averaging out its price from different pharmacy chains available 
online. All costs were converted to 2013 US dollars. Effectiveness data and data on 
transition probabilities were derived from a published clinical trial. The model was 
run over a 12-week period using TreeAge Pro 2013. Results: The cost associated with 
SFC treatment was estimated to be $1244 with 3 asthma controlled weeks and the cost 
associated with MF was $2884 with 1 asthma controlled week. The results showed that 
treatment with MF was dominated by SFC. ConClusions: This preliminary study 
shows that asthma management with SFC offers more treatment advantage and costs 
less compared to MF, therefore is more cost-effective than MF in asthma management.
PRS46
RESouRCES foR imPlEmEnting tRAnSition2quit, A Smoking CESSAtion 
intERvEntion foR hoSPitAlizEd SmokERS
Pisu M., Kim Y.I., Bailey WC, Harrington K.
University of Alabama at Birmingham, Birmingham, AL, USA
objeCtives: Web-based interventions are promising smoking cessation tools. We 
are testing the effectiveness of Transition2Quit, a tailored web-based and e-mes-
sage program for hospitalized smokers, versus usual care (minimal advice through 
non-tailored printed materials). We present data on resources to implement 
Transition2Quit. Methods: Interventionists approached smokers during hospitali-
zations to register and orient them to the website (onsite registration). Staff made 
≥ 5 attempts at a follow-up contact 7-14 days post-discharge. Through the website, 
we tracked follow-up calls and web activity. Interventionists recorded start and fin-
ish times of their activities. Results: Of 737 smokers, 54.4% were male, 27.4% had 
cancer, 29.2% heart disease/stroke, 13.3% lung disease, 15.6 surgery or wound healing, 
and the rest other conditions. Mean age was 41.6 years. Onsite registration lasted 
8-41 minutes (mean 17.6, median 16, SD 8.23), usual care 0-6 minutes (mean 2, SD 1). 
Interventionists attempted 2.9 calls per person (SD 1.9, max 9). 129 participants could 
not be reached due to disconnected phones, death, or ≥ 5 call attempts. For 43.4% ≥ 1 
call was placed on weekends, for 69% in the evening. Follow-up calls lasted an average 
of 2.4 minutes (median 3, SD 0.9). 700 participants accessed the website 15.4 times 
(SD 17.1), on 1.98 days (SD 3.39), and accessed 5.39 pages (SD 4.06). Women were more 
likely to access the website than men (16.9 vs 14.2, p 0.04). Participants with heart dis-
ease accessed 18.4 times (SD 23.6), with cancer 15.4 (SD 13.8), with surgery or wound 
healing 15.2 (SD 13.0), with lung disease 12.9 (SD 10.7), with other condition 12.2 (SD 
14.5) (p= 0.018). ConClusions: Transition2Quit required minimal staff resources: 
to better inform dissemination, further understanding on how requirements vary 
depending on populations’ characteristics (e.g., age, health condition) is needed. The 
website content may need to be better tailored to men and lung disease patients.
RESPiRAtoRy-RElAtEd diSoRdERS – Patient-Reported outcomes & Patient 
Preference Studies
PRS47
long-tERm ContRollER mEdiCAtion AdhEREnCE And uSE of ShoRt-
ACting Β2-AgoniStS (SAbA) And oRAl CoRtiCoStERoidS (oCS) Among 
tExAS mEdiCAid PAtiEntS With PERSiStEnt ASthmA
Makhinova T., Barner J.C., Richards K.M., Rascati K.L.
University of Texas at Austin, Austin, TX, USA
objeCtives: To determine if there is a relationship between asthma long-term 
controller (LTC) adherence and short-acting β 2-agonist (SABA)/oral corticosteroid 
(OCS) use. Methods: Texas Medicaid prescription claims from 7/1/2008-8/31/2010 
for continuously enrolled patients aged 5-63 years diagnosed with asthma (ICD-9 
493.xx) and who had persistent asthma were included in this retrospective database 
study. Patients were followed for one year after the first (index) asthma controller 
prescription. The primary outcomes were SABA use (dichotomous: < 6 vs. ≥ 6) and 
OCS use (continuous). The primary independent variable was adherence [Proportion 
of Days Covered (PDC)] to asthma LTCs. Covariates included demographics and 
